Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion

Al-Dimassi,Saleh; Salloum,Gilbert; Saykali,Bechara; Khoury,Oula; Liu,Shihui; Leppla,Stephen H.; Abi-Habib,Ralph; El-Sibai,Mirvat

doi:10.3892/ijo.2016.3431

Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion

Authors:
- Saleh Al-Dimassi
- Gilbert Salloum
- Bechara Saykali
- Oula Khoury
- Shihui Liu
- Stephen H. Leppla
- Ralph Abi-Habib
- Mirvat El-Sibai
View Affiliations

Affiliations: Department of Natural Sciences, The Lebanese American University, Beirut 1102 2801, Lebanon, Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Published online on: March 9, 2016 https://doi.org/10.3892/ijo.2016.3431
Pages: 1913-1920

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant astrocytomas are highly invasive into adjacent and distant regions of the normal brain. Understanding and targeting cancer cell invasion is an important therapeutic approach. Cell invasion is a complex process that replies on many signaling pathways including the mitogen-activated protein (MAP) kinase (MAPK). In many cell lines, the use of MAPK-targeted drugs proved to be a potential method to inhibit cancer cell motility. In the present study, we use a recombinant anthrax lethal toxin (LeTx), which selectively inhibits the MAPK pathway, in order to target invasion. LeTx proved ineffective on cell survival in astrocytoma (as well as normal cells). However, astrocytoma cells that were treated with LeTx showed a significant decrease in cell motility as seen by wound healing as well as random 2D motility in serum. The cells also showed a decrease in invasion across a collagen matrix. The effect of LeTx on cell migration was mediated though the deregulation of Rho GTPases, which play a role in cell motility. Finally, the effect of LeTx on cell migration and Rho GTPases was mimicked by the inhibition of the MAPK pathway. In this study, we describe for the first time the effect of the LeTx on cancer cell motility and invasion not cell survival making it a potentially selective brain tumor invasion inhibitor.

View Figures

View References

1	Deorah S, Lynch CF, Sibenaller ZA and Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 20:E12006. View Article : Google Scholar : PubMed/NCBI
2	von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR and Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3:19–26. 1993. View Article : Google Scholar : PubMed/NCBI
3	DeAngelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
4	Moon SY and Zheng Y: Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003. View Article : Google Scholar
5	Yamazaki D, Kurisu S and Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci. 96:379–386. 2005. View Article : Google Scholar : PubMed/NCBI
6	El-Sibai M, Pertz O, Pang H, Yip SC, Lorenz M, Symons M, Condeelis JS, Hahn KM and Backer JM: RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent protrusion in MTLn3 carcinoma cells. Exp Cell Res. 314:1540–1552. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ananthakrishnan R and Ehrlicher A: The forces behind cell movement. Int J Biol Sci. 3:303–317. 2007. View Article : Google Scholar : PubMed/NCBI
8	Vega FM, Fruhwirth G, Ng T and Ridley AJ: RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol. 193:655–665. 2011. View Article : Google Scholar : PubMed/NCBI
9	El-Sibai M and Backer JM: Phospholipase C γ negatively regulates Rac/Cdc42 activation in antigen-stimulated mast cells. Eur J Immunol. 37:261–270. 2007. View Article : Google Scholar
10	Moorman JP, Luu D, Wickham J, Bobak DA and Hahn CS: A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene. 18:47–57. 1999. View Article : Google Scholar : PubMed/NCBI
11	Ridley AJ: RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc. 251:242–249. 2013. View Article : Google Scholar : PubMed/NCBI
12	Buchsbaum RJ: Rho activation at a glance. J Cell Sci. 120:1149–1152. 2007. View Article : Google Scholar : PubMed/NCBI
13	O'Connor K and Chen M: Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases. 4:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ridley AJ: Life at the leading edge. Cell. 145:1012–1022. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ellenbroek SI and Collard JG: Rho GTPases: Functions and association with cancer. Clin Exp Metastasis. 24:657–672. 2007. View Article : Google Scholar : PubMed/NCBI
16	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
17	Boettner B and Van Aelst L: The role of Rho GTPases in disease development. Gene. 286:155–174. 2002. View Article : Google Scholar : PubMed/NCBI
18	Khalil BD, Hanna S, Saykali BA, El-Sitt S, Nasrallah A, Marston D, El-Sabban M, Hahn KM, Symons M and El-Sibai M: The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility. Exp Cell Res. 321:109–122. 2014. View Article : Google Scholar
19	Lauffenburger DA and Horwitz AF: Cell migration: A physically integrated molecular process. Cell. 84:359–369. 1996. View Article : Google Scholar : PubMed/NCBI
20	Bermudez O, Pagès G and Gimond C: The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am J Physiol Cell Physiol. 299:C189–C202. 2010. View Article : Google Scholar : PubMed/NCBI
21	Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
22	Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 5:810–816. 1999. View Article : Google Scholar : PubMed/NCBI
23	Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene. 20:4209–4218. 2001. View Article : Google Scholar : PubMed/NCBI
24	Zohrabian VM, Forzani B, Chau Z, Murali R and Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 29:119–123. 2009.PubMed/NCBI
25	Bradley KA, Mogridge J, Mourez M, Collier RJ and Young JA: Identification of the cellular receptor for anthrax toxin. Nature. 414:225–229. 2001. View Article : Google Scholar : PubMed/NCBI
26	Scobie HM, Rainey GJ, Bradley KA and Young JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA. 100:5170–5174. 2003. View Article : Google Scholar : PubMed/NCBI
27	Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS and Frankel AE: BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther. 4:1303–1310. 2005. View Article : Google Scholar : PubMed/NCBI
28	Abrami L, Liu S, Cosson P, Leppla SH and van der Goot FG: Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol. 160:321–328. 2003. View Article : Google Scholar : PubMed/NCBI
29	Melnyk RA and Collier RJ: A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation. Proc Natl Acad Sci USA. 103:9802–9807. 2006. View Article : Google Scholar : PubMed/NCBI
30	Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, et al: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
31	During RL, Li W, Hao B, Koenig JM, Stephens DS, Quinn CP and Southwick FS: Anthrax lethal toxin paralyzes neutrophil actin-based motility. J Infect Dis. 192:837–845. 2005. View Article : Google Scholar : PubMed/NCBI
32	Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 92:7686–7689. 1995. View Article : Google Scholar : PubMed/NCBI
33	Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, et al: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:734–737. 1998. View Article : Google Scholar : PubMed/NCBI
34	Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS and Frankel AE: Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res. 12:7437–7443. 2006. View Article : Google Scholar : PubMed/NCBI
35	Chopra AP, Boone SA, Liang X and Duesbery NS: Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem. 278:9402–9406. 2003. View Article : Google Scholar : PubMed/NCBI
36	Ha SD, Ng D, Pelech SL and Kim SO: Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages. J Biol Chem. 282:36230–36239. 2007. View Article : Google Scholar : PubMed/NCBI
37	Hanna S and El-Sibai M: Signaling networks of Rho GTPases in cell motility. Cell Signal. 25:1955–1961. 2013. View Article : Google Scholar : PubMed/NCBI